PrEP Access Act

Legislative bill overview

HR 7189, the PrEP Access Act, aims to improve access to pre-exposure prophylaxis (PrEP)—medications that prevent HIV infection—by addressing barriers to obtaining and affording these preventive treatments. The bill likely includes provisions related to insurance coverage, medication affordability, and removal of regulatory or administrative obstacles to PrEP availability. It has been referred to the Energy and Commerce Committee and Ways and Means Committee for consideration.

Why is this important

PrEP is highly effective at preventing HIV transmission when taken consistently, yet access remains unequal across income levels, geography, and demographics. Expanding PrEP access could reduce new HIV infections and associated healthcare costs, while improving public health outcomes for at-risk populations. The bill addresses a documented gap between clinical evidence supporting PrEP's effectiveness and real-world availability constraints.

Potential points of contention

• Cost and funding: Debate over who bears financial responsibility—whether insurance companies, government programs (Medicaid/Medicare), or individuals should cover costs, and the overall budgetary impact
• Insurance coverage mandates: Potential disagreement on whether insurers should be required to cover PrEP without cost-sharing, which could increase premiums
• Scope of eligibility: Questions about which populations qualify for coverage and whether risk-based or universal access criteria should apply